INSYS (INSY) Syndros Should Have Solid Uptake - Piper Jaffray
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Wells Fargo raises oil price targets citing ongoing supply risks
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
Insys Therapeutics (INSY): Syndros Approval Should Contribute $220M - RBC
July 5, 2016 8:45 AM EDTRBC Capital analyst, Randall Stanicky, noted that this morning, INSYS Therapeutics (NASDAQ: INSY) announced that it has received approval for Syndros (Dronabinol OS), its cannabinoid dronabinol oral solution. The product will be used to treat AIDS-related anorexia and nausea and vomiting in patients receiving... More
Insys Therapeutics' (INSY) Syndros Approved by FDA
July 5, 2016 6:56 AM EDTInsys Therapeutics, Inc. (Nasdaq: INSY) announced that the U.S. Food and Drug Administration (FDA) has approved Insys dronabinol oral solution, Syndros, an orally administered liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol ("THC"). Syndros is approved for use in treating anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. Syndros is currently awaiting scheduling by the U.S. Drug Enforcement Administration.
"We are very pleased... More
